Edition:
United States

Biofrontera AG (B8FGn.F)

B8FGn.F on Frankfurt Stock Exchange

4.13EUR
24 May 2017
Change (% chg)

€0.15 (+3.77%)
Prev Close
€3.98
Open
€3.91
Day's High
€4.14
Day's Low
€3.91
Volume
7,000
Avg. Vol
24,932
52-wk High
€4.87
52-wk Low
€2.20

Latest Key Developments (Source: Significant Developments)

Biofrontera enters into finance contract with European Investmentbank
Friday, 19 May 2017 06:20am EDT 

May 19 (Reuters) - BIOFRONTERA AG ::BIOFRONTERA ENTERS INTO FINANCE CONTRACT WITH EUROPEAN INVESTMENTBANK.EIB WILL PROVIDE A LOAN OF UP TO EUR 20 MILLION TO BIOFRONTERA-GROUP.  Full Article

Biofrontera Q1 net loss at 3.5 million euros
Friday, 19 May 2017 02:34am EDT 

May 19 (Reuters) - BIOFRONTERA AG :SALES INCREASED C. 160% TO EUR2.6 MILLION FOR Q1 2017, COMPARED TO EUR1.0 MILLION IN SAME PERIOD 2016..NET LOSS WAS EUR(3.5) MILLION FOR Q1 2017, COMPARED TO EUR(448) THOUSAND FOR SAME PERIOD IN 2016..RESEARCH AND DEVELOPMENT COSTS AMOUNTED TO EUR1.1 MILLION IN Q1, AN INCREASE OF 12%, YEAR-OVER-YEAR. THESE COSTS WERE MAINLY DUE TO DEVELOPMENT PARTNERSHIPS..INTENDS TO APPLY FOR BCC APPROVAL IN U.S., AND HAS APPLIED FOR A MEETING WITH FDA, WHICH IS EXPECTED TO BE HELD IN Q2 OF 2017.  Full Article

Biofrontera FY sales up 48 pct at 6.1 million euros
Wednesday, 12 Apr 2017 02:00am EDT 

Biofrontera AG : Sales increased 48 pct to 6.1 million euros ($6.47 million) for full year 2016 compared to 4.1 million euros in 2015 . Operational result was -11.8 million euros for full year 2016 compared to -10.2 million euros for 2015 .Net loss before taxes was -10.6 million euros for full year 2016, as compared to -11.2 million euros for same period in previous year.  Full Article

Biofrontera reports detailed phase III results for Ameluz
Monday, 13 Mar 2017 04:00am EDT 

Biofrontera AG : Reports detailed phase III results for Ameluz in combination with daylight-PDT . Data show daylight photodynamic therapy (PDT) with Ameluz provided excellent results for primary and all secondary study endpoints .EMA filing for EU approval of daylight PDT for actinic keratosis (AK) expected in Q2 2017.  Full Article

Biofrontera: positive prelim results for primary endpoint of Phase III clinical trial (Ameluz)
Tuesday, 7 Feb 2017 02:03am EST 

Biofrontera AG : Reported on Monday it receives positive preliminary results for the primary endpoint of its Phase III clinical trial evaluating the safety and efficacy of its topical drug BF-200 ALA (Ameluz) in combination with daylight photodynamic therapy (PDT) .Results will be employed for the filing of the EU label extension, which Biofrontera plans to submit in the second quarter of 2017.  Full Article

Biofrontera: EMA recommends indication expansion of ameluz for treatment of basal cell carcinoma
Tuesday, 20 Dec 2016 10:30am EST 

Biofrontera AG : European Medicines Agency recommends indication expansion of ameluz for treatment of basal cell carcinoma .Approval by European Commission expected in next few weeks.  Full Article

Biofrontera 9-month sales up 9 pct at 2.881 mln euros
Wednesday, 30 Nov 2016 02:08am EST 

Biofrontera AG : Sales increased 9 pct to 2.881 million euros for first nine months 2016 compared to 2.635 million euros in same period 2015 . Guidance for full year remains unchanged .Net income loss before taxes was (7.164) million euros for first nine months of 2016, as compared to (9.286) million euros for same period in previous year.  Full Article

Biofrontera: capital increase 5,012,950 new shares fully placed
Thursday, 17 Nov 2016 05:27am EST 

Biofrontera AG :Capital increase: 5,012,950 new shares fully placed.  Full Article

Biofrontera resolves on capital increase and issue of convertible bonds
Tuesday, 1 Nov 2016 02:29am EDT 

Biofrontera AG : Said on Monday resolves on capital increase and issue of convertible bonds . To increase the registered capital of the Company from currently 30,347,813 euros by up to 5,012,950 euros ($5.50 million) to up to 35,360,763 euros by issuing up to 5,012,950 new no-par registered shares with a calculatory participation in the registered capital of 1.00 euro . To issue up to 49,990 subordinate convertible bonds with a nominal amount of 100 euros each and in a total nominal amount of 4,999,000 euros . Bonds mature on Dec. 31, 2020 . Each Bond may be converted into ordinary shares of the Company at a calculatory participation in the registered capital of 1.00 euro and dividend rights from the year of the issue . The conversion price of bonds will initially be 3.00 euros per share, from Jan. 1, 2017 4.00 euros per share and from Jan. 1, 2018 5.00 euros per share .Intends to use the expected net proceeds of approx. 19.5 million euros for the repayment of the bond due on Jan. 1, 2017 in an amount of about 9 million euros, as well as to finance the commercialization of Ameluz in the USA and covering ongoing costs of operations.  Full Article

Biofrontera H1 sales up 9 pct at 1.709 million euros
Wednesday, 31 Aug 2016 02:00am EDT 

Biofrontera AG : Sales increased 9 pct to 1.709 million euros ($1.90 million)in H1 2016 compared to 1.568 million euros in H1 2015 . Net income loss was 3.472 million euros in H1 2016 compared to 7.323 million euros in H1 2015 .Cash on balance sheet was 10.2 million euros as of June 30.  Full Article

More From Around the Web